熱點掃描 | 醫藥外包概念普跌，藥明生物跌超4%
uSMART盈立智投4月7日消息，截止發稿，港股三大指數齊跌，恆生指數下跌0.27%，報22065.1點，成交額488.34億；國企指數下跌0.03%，報7603.38點，成交額160.74億；紅籌指數下跌0.69%，報4091.06點，成交額26.82億。
煤炭股拉昇，兗煤澳大利亞漲超4%，中國神華漲近2%，伊泰煤炭、易大宗漲逾1%；
體育用品板塊走高，李寧、滔搏漲2%，波司登、安踏漲超1%；
抗疫概念股多數走低，開拓藥業跌超12%，康希諾生物、歌禮制藥跌5%，復星醫藥、三葉草生物跌超4%；
醫藥外包概念普跌，藥明生物跌超4%，藥明康德、康龍化成、泰格醫藥跌超2%。
熱門股
香港航天科技再度拉昇漲超14%，3日累計漲幅近60%，現報20.8港元，公司日前公告2021年收入升18.7%至6.5億元。公司金紫荊-齊魯衛星星座第一期將由9顆衛星組成，其建造和發射將於今年完成。其中，首發試驗星金紫荊衛星六號，預計今年7月發射。此前公司擬與香港城市大學工學院合作研發先進衛星科技及相關應用。2023年集團將繼續投產批量多顆遙感衛星；
百濟神州漲約3.7%，報128.9港元，百濟神州亦漲2.69%。百濟神州公佈，百澤安(替雷利珠單抗注射液)用於治療既往接受過全身化療的晚期或轉移性食管鱗狀細胞癌(ESCC)患者，以及非小細胞肺癌(NSCLC)患者的上市許可申請(MAA)已獲得歐洲藥品管理局(EMA)受理，目前正在審評中。該申請由百澤安歐洲許可持有人諾華提交；
賞之味再度下挫10%，報0.091港元，四日累跌超76%，低見0.082港元創逾一年新低。賞之味公佈，主要股東Brilliant Trade於4月6日在聯交所公開市場上出售2,700萬股公司股份，佔公司已發行股份總數約5.4%，平均代價約爲每股0.094元，總代價爲約253.5萬元。緊隨出售事項後，Brilliant Trade所持公司權益佔比由25.4%降至20%，仍然爲公司主要股東。此前，Brilliant Trade於4月4日在聯交所公開市場上出售3903.5萬股公司股份，套現約1237.1萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
